Focus and Innovation

Focus and Innovation

Focus and Innovation

Focus and Innovation

The commercial success of our approved products allows us to continue to invest in our R&D pipeline, which is crucial for the future success of our company.

Basilea at a glance

Basilea is a revenue-generating, commercial-stage Swiss biopharmaceutical company. Our activities are focused in the areas of hospital antibiotics and hospital antifungals. Our portfolio comprises of two marketed anti-infective brands (Cresemba® and Zevtera®) and several preclinical anti-infective assets. We are building on our potential for sustainable growth and valuation generation, based on increasing revenues and selective investments into internal and external innovation. Basilea was founded in 2000 and is located in the life sciences hub of the Basel area. Basilea has about 150 employees. Since 2004, Basilea is listed on the SIX Swiss Stock Exchange with the ticker symbol BSLN.

Vision and mission

People are at the heart of everything we do. We strive towards making a difference to patients. With expertise, care and persistence. We aim to be a leading provider of innovative medicines. For the benefit of patients.

Organization

Board of Directors

 

Board Committees

Audit Committee Compensation Committee Corporate Governance & Nomination Committee
Leonard Kruimer
(Chairman)
Dr. Martin Nicklasson
(Chairman)
Dr. Thomas Werner
(Chairman)
Dr. Martin Nicklasson Dr. Nicole Onetto Domenico Scala
Steven D. Skolsky Dr. Thomas Werner Steven D. Skolsky 

For further information on the responsibilities of the Board committees, please refer to the latest annual report.

Management Committee

 

Extended Management Committee